UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/781,426	02/18/2004	David J. Jorgenson	P-8050.05	3045
27581 MEDTRONIC,	7590 05/18/200 INC	7	EXAMINER	
710 MEDTRONIC PARKWAY NE			HOLMES, REX R	
MINNEAPOLIS, MN 55432-9924			ART UNIT	PAPER NUMBER
			3762	
			MAIL DATE	DELIVERY MODE
			05/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		XX				
	Application No.	Applicant(s)				
Office Antique Commence	10/781,426	JORGENSON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Rex Holmes	3762				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be to will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	NN. imely filed m the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 20 F	ebruary 2007.					
2a)⊠ This action is FINAL . 2b)☐ This	s action is non-final.					
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims		•				
4) ⊠ Claim(s) <u>17-21</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrays 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>17-21</u> is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	wn from consideration.					
Application Papers						
9)☐ The specification is objected to by the Examine	er.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applica rity documents have been receiv u (PCT Rule 17.2(a)).	ition No ved in this National Stage				
200 this altability dotained control about 101 a list of the dotained copies flot 1000/104.						
Attachment(e)						
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail [

U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06) Application/Control Number: 10/781,426 Page 2

Art Unit: 3762

DETAILED ACTION

Response to Arguments

1. Applicant's arguments with respect to claim 17-20 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 4. Claims 17-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cinbis et al. (U.S. Pat. 5,897,577 hereinafter "Cinbis") in view of Juran et al. (U.S. Pat. 6,016,447 hereinafter "Juran").

Page 3

Application/Control Number: 10/781,426

Art Unit: 3762

- 5. Regarding claims 17-18, Cinbis discloses a pacing lead impedance monitoring circuit for use in an implantable medical device designed to collect lead impedance data (Col. 5, 56-65), stimulation threshold data (Col. 2, II. 21-32), and other data that may be non-physiological data (Col. 8, II. 8-16). Cinbis further discloses that once it is determined that the leads are no longer functional a signal is created to indicate the status (Col. 9, II. 5-9), but Cinbis does not disclose a time from implant source. However, Juran discloses a pacemaker that includes a time from implant source and states that the device may use the implant time to trigger various therapy programs automatically. (Col. 4, II. 41-49 & Col. 5, II. 50-54). It would have been obvious to one having ordinary skill in the art at the time the invention was made have modified the lead status monitoring system as taught by Cinbis with the time from implant source as disclosed by Juran in order to keep track of the time since implant to determine time decay and to base and automatically adjust the pacing based on pre-measured decay.
- 6. Claims 19-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cinbis in view of Juran as applied to claims 17-18 above, and further in view of Dutcher et al. (U.S. Pat. 4,140,131 hereinafter "Dutcher").
- 7. Regarding claims 19-21, Cinbis in view of Juran discloses the lead status monitoring system as discussed in detail above, but does not explicitly disclose that finds a biological interface issue, explicitly a myocardial perforation. However, Dutcher discloses a stimulation-warning device where impedance level detectors determine the possibility of lead rupture (Col. 6, II. 14-22; Fig. 1A, 18). It would have been obvious to one having ordinary skill in the art at the time the invention was made to have modified

Application/Control Number: 10/781,426

Art Unit: 3762

he lead status monitoring system as taught by Cinbis in view of Juran with the rupture detection system as taught by Dutcher in order to determine lead failure by determining the proper placement of the leads before application of the stimulation.

8. It is noted that Cinbis in view of Juran and further in view of Dutcher do not explicitly state that they assign weighted values to the collected data, Dutcher inherently assigns a value to determine if a lead status event has occurred, otherwise the monitoring system would either always detect a event or never detect an event.

Conclusion

9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 10/781,426

Art Unit: 3762

426 Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rex Holmes whose telephone number is 571-272-8827. The examiner can normally be reached on M-F 8:00 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on 571-272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rex Holmes

George Evanisko

Primary Examiner

5/14/7